Intensity Therapeutics Common stock logo

Intensity Therapeutics Common stockNASDAQ: INTS

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

30 June 2023

Next earnings report:

13 November 2024

Last dividends:

N/A

Next dividends:

N/A
$43.97 M
-64%vs. 3y high
33%vs. sector
-vs. 3y high
-vs. sector
-36%vs. 3y high
90%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | 13 min ago
$3.19-$0.11(-3.20%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

INTS Latest News

Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
prnewswire.com08 August 2024 Sentiment: POSITIVE

First patient dosed in global randomized, Phase 3 study in metastatic soft tissue sarcoma Collaboration agreement with The Swiss Group for Clinical Cancer Research SAKK ("SAKK") to conduct a Phase 2 randomized, study in early-stage breast cancer in Europe Cash and investments of $6.3 million expected to fund operations into the first quarter of 2025 SHELTON, Conn. , Aug. 8, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces second quarter 2024 financial results and provides a corporate update.

Intensity Therapeutics to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update
PRNewsWire07 August 2023 Sentiment: NEGATIVE

Webcast to be Held at 8:00 am ET on Monday, August 14, 2023 WESTPORT, Conn. , Aug. 7, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (Intensity) (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that it report its financial results for the second quarter ended June 30, 2023, including a corporate update, on Monday, August 14, 2023, before the opening of the U.S. financial markets.

What type of business is Intensity Therapeutics Common stock?

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States. Its lead product candidate includes INT230-6, which is in human clinical studies for the treatment of refractory solid tumors, such as soft tissue sarcoma which is in phase 3 trails; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

What sector is Intensity Therapeutics Common stock in?

Intensity Therapeutics Common stock is in the Healthcare sector

What industry is Intensity Therapeutics Common stock in?

Intensity Therapeutics Common stock is in the Biotechnology industry

What country is Intensity Therapeutics Common stock from?

Intensity Therapeutics Common stock is headquartered in United States

When did Intensity Therapeutics Common stock go public?

Intensity Therapeutics Common stock initial public offering (IPO) was on 30 June 2023

What is Intensity Therapeutics Common stock website?

https://www.intensitytherapeutics.com

Is Intensity Therapeutics Common stock in the S&P 500?

No, Intensity Therapeutics Common stock is not included in the S&P 500 index

Is Intensity Therapeutics Common stock in the NASDAQ 100?

No, Intensity Therapeutics Common stock is not included in the NASDAQ 100 index

Is Intensity Therapeutics Common stock in the Dow Jones?

No, Intensity Therapeutics Common stock is not included in the Dow Jones index

When was Intensity Therapeutics Common stock the previous earnings report?

No data

When does Intensity Therapeutics Common stock earnings report?

The next expected earnings date for Intensity Therapeutics Common stock is 13 November 2024